Soleno Therapeutics Ownership 2024 | Who Owns Soleno Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

1.26%

Insider Ownership

1.53%

Retail Ownership

97.21%

Institutional Holders

2.00

Soleno Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TCG CROSSOVER MANAGEMENT, LLC3.33%1.86%550,000550,000100.00%23,540,000Mar 31, 2024

Soleno Therapeutics's largest institutional shareholder is TCG CROSSOVER MANAGEMENT, LLC, holding 3.33% of the company's total share outstanding, currently valued at $23.54M. The top 10 institutional shareholders own together 3.33% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TCG CROSSOVER MANAGEMENT, LLC3.33%1.86%550,000550,000100.00%23,540,000Mar 31, 2024

The largest Soleno Therapeutics shareholder by % of total assets is TCG CROSSOVER MANAGEMENT, LLC. The company owns 550.00K shares of Soleno Therapeutics (SLNO), representing 1.86% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TCG CROSSOVER MANAGEMENT, LLC3.33%1.86%550,000550,000100.00%23,540,000Mar 31, 2024

As of Mar 31 2024, Soleno Therapeutics's largest institutional buyer is TCG CROSSOVER MANAGEMENT, LLC. The company purchased 550.00K stocks of SLNO, valued at $23.54M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TCG CROSSOVER MANAGEMENT, LLC3.33%1.86%550,000550,000100.00%23,540,000Mar 31, 2024

As of Mar 31 2024, Soleno Therapeutics's biggest institutional seller is TCG CROSSOVER MANAGEMENT, LLC. The company sold 550.00K shares of SLNO, valued at $23.54M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TCG CROSSOVER MANAGEMENT, LLC3.33%1.86%550,000550,000100.00%23,540,000Mar 31, 2024

Soleno Therapeutics's largest new institutional shareholder by number of shares is TCG CROSSOVER MANAGEMENT, LLC, purchased 550.00K shares, valued at $23.54M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Soleno Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.02%9,839--Dec 31, 2023
QUANTITATIVE MASTER SERIES LLC0.02%105,332--Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 10.01%2,198--Dec 31, 2023
VANGUARD INDEX FUNDS0.00%1,950,152--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%123,492--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%1,156,5961,101,6452004.78%Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%66,304--Dec 31, 2023
TIAA-CREF LIFE FUNDS0.00%5,525--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%402,349--Feb 29, 2024
ETFis Series Trust I0.00%2,2072,207-Jan 31, 2024
FINANCIAL INVESTORS TRUST0.00%107,983--Jan 31, 2024
Calvert Variable Products, Inc.0.00%2,954--Dec 31, 2023
SunAmerica Specialty Series0.00%491--Apr 30, 2021
Voya VARIABLE PORTFOLIOS INC0.00%28,835--Dec 31, 2023
ProFunds0.00%5,5202,61289.82%Jan 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%14,59110,170230.09%Dec 31, 2023
PENN SERIES FUNDS INC0.00%9,4672,00026.78%Dec 29, 2023
ALLSPRING MASTER TRUST0.00%15,887--Feb 29, 2024
FIDELITY SALEM STREET TRUST0.00%517,907--Feb 29, 2024
PGIM ETF TRUST0.00%12,512--Feb 29, 2024
ProFunds0.00%1,292--Jan 31, 2024
HC CAPITAL TRUST0.00%3,995--Dec 31, 2023
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%11,000--Dec 31, 2023
VALIC Co I0.00%28,273--Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS0.00%189,525--Feb 29, 2024
PENN SERIES FUNDS INC0.00%2,600--Dec 29, 2023
NATIONWIDE VARIABLE INSURANCE TRUST0.00%11,408--Dec 31, 2023
PACE SELECT ADVISORS TRUST0.00%20,106--Jan 31, 2024
NATIONWIDE MUTUAL FUNDS0.00%7,175--Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%42,474--Dec 31, 2023
NORTHERN FUNDS0.00%31,902--Dec 29, 2023
T. Rowe Price Index Trust, Inc.0.00%603--Feb 29, 2024
MORGAN STANLEY PATHWAY FUNDS0.00%2,415--Feb 29, 2024
SUNAMERICA SERIES TRUST0.00%6,442--Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%15,466--Jan 31, 2024
SPDR SERIES TRUST0.00%462,912462,912-Dec 31, 2023
Dimensional ETF Trust0.00%5,288--Jan 31, 2024
EQ ADVISORS TRUST0.00%11,459--Dec 31, 2023
SEI INSTITUTIONAL MANAGED TRUST0.00%26,578-6,522-19.70%Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%18,275--Dec 31, 2023
EXCHANGE TRADED CONCEPTS TRUST0.00%46--Feb 29, 2024
PACIFIC SELECT FUND0.00%26,716--Dec 31, 2023
MASSMUTUAL SELECT FUNDS0.00%7,093--Dec 31, 2023
Pacer Funds Trust0.00%283283-Jan 31, 2024
ADVANCED SERIES TRUST0.00%22,647--Dec 29, 2023
NATIONWIDE MUTUAL FUNDS0.00%631631-Jan 31, 2024
Bridge Builder Trust0.00%21,044--Dec 31, 2023
Advisors' Inner Circle Fund III0.00%31--Jan 31, 2024
BlackRock Variable Series Funds, Inc.0.00%7,871--Dec 31, 2023
PRINCIPAL FUNDS, INC.0.00%9,877--Feb 29, 2024
John Hancock Funds II0.00%10,297--Feb 29, 2024
BLACKROCK FUNDS0.00%2,648--Feb 29, 2024

Soleno Therapeutics's largest mutual fund holder by % of total assets is "DEUTSCHE DWS INVESTMENTS VIT FUNDS", owning 9.84K shares, compromising 0.02% of its total assets.

Soleno Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Sep, 222-93.94%
30 Jun, 2233-
31 Mar, 2233-5.71%
31 Dec, 2135-2.78%
30 Sep, 2136-26.53%
30 Jun, 2149-22.22%
31 Mar, 2163-4.55%
31 Dec, 20664.76%
30 Sep, 2063-11.27%
30 Jun, 2071136.67%
31 Mar, 203066.67%
31 Dec, 19185.88%
30 Sep, 1917-5.56%
30 Jun, 1918-10.00%
31 Mar, 192025.00%
31 Dec, 181614.29%
30 Sep, 1814-12.50%
30 Jun, 1816100.00%
31 Mar, 188-
31 Dec, 178-

As of 30 Sep 22, 2 institutions are holding Soleno Therapeutics's shares, representing a decrease of -93.94% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Sep, 22102,288-99.77%
30 Jun, 2245,016,284-3.96%
31 Mar, 2246,870,80568.28%
31 Dec, 2127,853,132-1.84%
30 Sep, 2128,376,288-0.73%
30 Jun, 2128,583,907-9.89%
31 Mar, 2131,721,894-24.95%
31 Dec, 2042,265,2561.42%
30 Sep, 2041,674,3201.74%
30 Jun, 2040,959,91799.96%
31 Mar, 2020,484,00219.04%
31 Dec, 1917,207,80071.02%
30 Sep, 1910,062,024-30.11%
30 Jun, 1914,396,615-0.01%
31 Mar, 1914,397,730-2.74%
31 Dec, 1814,803,11367.28%
30 Sep, 188,849,4550.60%
30 Jun, 188,796,5065.09%
31 Mar, 188,370,2031.34%
31 Dec, 178,259,274-

Soleno Therapeutics (SLNO) has 102.29K shares outstanding as of 30 Sep 22, down -99.77% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Sep, 221.26%0.00%
30 Jun, 22562.29%0.07%
31 Mar, 22878.60%0.32%
31 Dec, 21523.75%0.18%
30 Sep, 21533.45%0.18%
30 Jun, 21537.65%0.15%
31 Mar, 21597.06%0.09%
31 Dec, 20796.37%0.13%
30 Sep, 20785.49%0.04%
30 Jun, 201328.83%0.28%
31 Mar, 20687.69%0.17%
31 Dec, 19627.02%0.28%
30 Sep, 19474.72%0.10%
30 Jun, 19679.58%0.15%
31 Mar, 19680.08%0.06%
31 Dec, 181058.60%0.28%
30 Sep, 18619.35%0.15%
30 Jun, 18648.54%0.16%
31 Mar, 18642.86%0.16%
31 Dec, 17634.34%-

As of 30 Sep 22, Soleno Therapeutics is held by 1.26% institutional shareholders, representing a 0.00% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Sep, 221-90.91%
30 Jun, 2211-15.38%
31 Mar, 221318.18%
31 Dec, 2111-21.43%
30 Sep, 2114-30.00%
30 Jun, 2120-23.08%
31 Mar, 2126-18.75%
31 Dec, 2032-13.51%
30 Sep, 2037-37.29%
30 Jun, 2059210.53%
31 Mar, 201972.73%
31 Dec, 191110.00%
30 Sep, 191025.00%
30 Jun, 198-33.33%
31 Mar, 191250.00%
31 Dec, 188-
30 Sep, 188-42.86%
30 Jun, 1814250.00%
31 Mar, 184-50.00%
31 Dec, 178-

1 institutional shareholders have increased their position in SLNO stock as of 30 Sep 22 compared to 11 in the previous quarter (a -90.91% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Sep, 221-90.00%
30 Jun, 2210-
31 Mar, 221066.67%
31 Dec, 216-
30 Sep, 216-66.67%
30 Jun, 2118-14.29%
31 Mar, 21215.00%
31 Dec, 202066.67%
30 Sep, 2012140.00%
30 Jun, 20525.00%
31 Mar, 204-20.00%
31 Dec, 19566.67%
30 Sep, 193-40.00%
30 Jun, 19566.67%
31 Mar, 193-
31 Dec, 183200.00%
30 Sep, 181-
30 Jun, 181-
31 Mar, 181-
31 Dec, 17--

1 institutional shareholders have reduced their position in SLNO stock as of 30 Sep 22 compared to 10 in the previous quarter (a -90.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Sep, 222-93.94%102,288-99.77%1.26%0.00%1-90.91%1-90.00%
30 Jun, 2233-45,016,284-3.96%562.29%0.07%11-15.38%10-
31 Mar, 2233-5.71%46,870,80568.28%878.60%0.32%1318.18%1066.67%
31 Dec, 2135-2.78%27,853,132-1.84%523.75%0.18%11-21.43%6-
30 Sep, 2136-26.53%28,376,288-0.73%533.45%0.18%14-30.00%6-66.67%
30 Jun, 2149-22.22%28,583,907-9.89%537.65%0.15%20-23.08%18-14.29%
31 Mar, 2163-4.55%31,721,894-24.95%597.06%0.09%26-18.75%215.00%
31 Dec, 20664.76%42,265,2561.42%796.37%0.13%32-13.51%2066.67%
30 Sep, 2063-11.27%41,674,3201.74%785.49%0.04%37-37.29%12140.00%
30 Jun, 2071136.67%40,959,91799.96%1328.83%0.28%59210.53%525.00%
31 Mar, 203066.67%20,484,00219.04%687.69%0.17%1972.73%4-20.00%
31 Dec, 19185.88%17,207,80071.02%627.02%0.28%1110.00%566.67%
30 Sep, 1917-5.56%10,062,024-30.11%474.72%0.10%1025.00%3-40.00%
30 Jun, 1918-10.00%14,396,615-0.01%679.58%0.15%8-33.33%566.67%
31 Mar, 192025.00%14,397,730-2.74%680.08%0.06%1250.00%3-
31 Dec, 181614.29%14,803,11367.28%1058.60%0.28%8-3200.00%
30 Sep, 1814-12.50%8,849,4550.60%619.35%0.15%8-42.86%1-
30 Jun, 1816100.00%8,796,5065.09%648.54%0.16%14250.00%1-
31 Mar, 188-8,370,2031.34%642.86%0.16%4-50.00%1-
31 Dec, 178-8,259,274-634.34%-8---

Soleno Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell750,000$47.80$35.85M7,668,093
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell351,242$45.13$15.85M7,316,851
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K24,310
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell888$41.67$37.00K23,422
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell3,104$41.12$127.64K65,024
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell2,071$41.67$86.29K62,953
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell888$41.67$37.00K50,924
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K41,812
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell11,383$41.12$468.10K160,387
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell7,597$41.67$316.54K152,790
Jan 29, 2024Yen Kristenofficer SEE REMARKSS-SaleSell397$48.30$19.18K25,640
Jan 29, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell832$48.30$40.19K43,142
Jan 29, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell2,527$48.30$122.05K171,770

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell750,000$47.80$35.85M7,668,093
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell351,242$45.13$15.85M7,316,851
Apr 30, 2024Manning Meredithofficer Chief Commercial OfficerSell128,000$46.31$5.93M-
Apr 30, 2024Huang Michael F.officer Sr. VP of Clinical DevelopmentSell120,000$21.93$2.63M-
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K24,310
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell888$41.67$37.00K23,422
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell3,104$41.12$127.64K65,024
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell2,071$41.67$86.29K62,953
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell888$41.67$37.00K50,924
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K41,812
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell11,383$41.12$468.10K160,387
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell7,597$41.67$316.54K152,790
Jan 29, 2024Yen Kristenofficer SEE REMARKSS-SaleSell397$48.30$19.18K25,640
Jan 29, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell832$48.30$40.19K43,142
Jan 29, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell2,527$48.30$122.05K171,770
Jan 10, 2024MARIO ERNESTdirector-G-GiftSell3,523--124,566

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell750,000$47.80$35.85M7,668,093
May 01, 2024Vivo Opportunity, LLC10 percent owner-S-SaleSell351,242$45.13$15.85M7,316,851
Apr 30, 2024Manning Meredithofficer Chief Commercial OfficerSell128,000$46.31$5.93M-
Apr 30, 2024Huang Michael F.officer Sr. VP of Clinical DevelopmentSell120,000$21.93$2.63M-
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K24,310
Apr 03, 2024Yen Kristenofficer SEE REMARKSS-SaleSell888$41.67$37.00K23,422
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell3,104$41.12$127.64K65,024
Apr 03, 2024Mackaness James Hofficer CHIEF FINANCIAL OFFICERS-SaleSell2,071$41.67$86.29K62,953
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell888$41.67$37.00K50,924
Apr 03, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell1,330$41.12$54.69K41,812
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell11,383$41.12$468.10K160,387
Apr 03, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell7,597$41.67$316.54K152,790
Jan 29, 2024Yen Kristenofficer SEE REMARKSS-SaleSell397$48.30$19.18K25,640
Jan 29, 2024Hirano Patricia Cofficer SEE REMARKSS-SaleSell832$48.30$40.19K43,142
Jan 29, 2024Anish Bhatnagardirector, officer CHIEF EXECUTIVE OFFICERS-SaleSell2,527$48.30$122.05K171,770
Jan 10, 2024MARIO ERNESTdirector-G-GiftSell3,523--124,566
Jan 08, 2024Yen Kristenofficer See RemarksA-AwardBuy24,000--26,037
Jan 08, 2024Yen Kristenofficer See RemarksA-AwardBuy16,000$36.70$587.20K16,000
Jan 08, 2024Mackaness James Hofficer Chief Financial OfficerA-AwardBuy56,000--68,128
Jan 08, 2024Mackaness James Hofficer Chief Financial OfficerA-AwardBuy37,000$36.70$1.36M37,000

The last insider sell of Soleno Therapeutics's stock was made by Vivo Opportunity, LLC on May 01 2024, selling 750,000 shares at $47.80 per share (valued at $35.85M).

Soleno Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024-12-
Q1 202484200.00%
Q4 2023104223.81%
Q3 20232021000.00%
Q2 202336--
Q1 20234--
Q4 2022-31-
Q3 202271838.89%
Q2 20225--
Q1 2022223733.33%
Q4 202131300.00%
Q3 20214580.00%
Q2 2021117157.14%
Q1 2021122254.55%
Q4 20204666.67%
Q3 20204--
Q2 2020192950.00%
Q1 20208--
Q4 201951827.78%
Q3 20192--

0 total buy trades, and 12 total sell trades (buy/sell ratio of 0.00%) were made by Soleno Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024-10-
Q1 2024-3-
Q4 2023-31-
Q3 202316--
Q2 202314--
Q1 2023---
Q4 2022-31-
Q3 2022-18-
Q2 2022---
Q1 2022152750.00%
Q4 2021---
Q3 20211425.00%
Q2 2021-6-
Q1 2021-15-
Q4 2020-6-
Q3 2020---
Q2 202062300.00%
Q1 2020---
Q4 201951827.78%
Q3 20192--

As of Q2 2024, Insider owners conducted 0 open market buy trades and 10 open market sell trades of Soleno Therapeutics's stocks.

Soleno Therapeutics Peer Ownership


TickerCompany
ABOSAcumen Pharmaceuticals, Inc.
MBRXMoleculin Biotech, Inc.
CAPRCapricor Therapeutics, Inc.
ALRNAileron Therapeutics, Inc.
VECTVectivBio Holding AG
XFORX4 Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
DAWNDay One Biopharmaceuticals, Inc.
DFFNCervoMed Inc.
ANNXAnnexon, Inc.
BPTHBio-Path Holdings, Inc.
PULMPulmatrix, Inc.
AKTXAkari Therapeutics, Plc
BOLTBolt Biotherapeutics, Inc.
ONTXTraws Pharma, Inc.
LYRALyra Therapeutics, Inc.
CBIOGyre Therapeutics, Inc.
BNTCBenitec Biopharma Inc.

SLNO Ownership FAQ


Soleno Therapeutics is owned by institutional shareholders (1.26%), insiders (1.53%), and public (97.21%). The largest institutional shareholder of Soleno Therapeutics is TCG CROSSOVER MANAGEMENT, LLC (3.33% of total shares) and the top mutual fund owner is DEUTSCHE DWS INVESTMENTS VIT FUNDS (0.02% of total shares).

Soleno Therapeutics's major institutional shareholders are TCG CROSSOVER MANAGEMENT, LLC. The top five shareholders own together 3.33% of the company's share outstanding.

As of Sep 2022, there are 2 institutional shareholders of Soleno Therapeutics.

TCG CROSSOVER MANAGEMENT, LLC owns 550K shares of Soleno Therapeutics, representing 3.33% of the company's total shares outstanding, valued at $23.54M (as of Mar 2024).